Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Return on Equity (2021 - 2025)

Historic Return on Equity for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to 1.04%.

  • Lyell Immunopharma's Return on Equity fell 7000.0% to 1.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.04%, marking a year-over-year decrease of 7000.0%. This contributed to the annual value of 0.65% for FY2024, which is 3400.0% down from last year.
  • Lyell Immunopharma's Return on Equity amounted to 1.04% in Q3 2025, which was down 7000.0% from 1.06% recorded in Q2 2025.
  • Lyell Immunopharma's Return on Equity's 5-year high stood at 0.74% during Q1 2021, with a 5-year trough of 1.06% in Q2 2025.
  • Its 5-year average for Return on Equity is 0.37%, with a median of 0.26% in 2022.
  • The largest annual percentage gain for Lyell Immunopharma's Return on Equity in the last 5 years was 3300bps (2022), contrasted with its biggest fall of -9900bps (2022).
  • Lyell Immunopharma's Return on Equity (Quarter) stood at 0.22% in 2021, then rose by 2bps to 0.22% in 2022, then crashed by -52bps to 0.33% in 2023, then tumbled by -122bps to 0.73% in 2024, then tumbled by -42bps to 1.04% in 2025.
  • Its Return on Equity was 1.04% in Q3 2025, compared to 1.06% in Q2 2025 and 0.94% in Q1 2025.